Dermapharm Holding Se · XETR:DMP

Dermapharm — H1 2022 Earnings Presentation

18 slides from Dermapharm's earnings presentation, Sep 7, 2022

  1. Slide 1: Investors' and Analysts' Conference Call H1 2022

    INVESTORS’ AND ANALYSTS’ CONFERENCE CALL H1 2022 Grünwald, 7 September 2022

  2. Slide 2: Agenda H1 2022

    AGENDA H1 2022 1. Highlights H1 2022 2. Financial figures H1 2022 3. Outlook 2022 4. Q&A 2

  3. Slide 3: 1 Highlights H1 2022

    1 Highlights H1 2022 awa

  4. Slide 4: Highlights 6M 2022

    Highlights 6M 2022 Successful first half of 2022 in challenging market environment Continuous growth in Branded Pharmaceuticals Broadly diversified product portfolio as important guarantee for growth in selected therapeutic areas supported by ongoing vaccine production Strengthening of segment Herba

  5. Slide 5: 2 Financial figures H1 2022

    2 Financial figures H1 2022 5

  6. Slide 6: Dermapharm Group

    Dermapharm Group Growth impulses from vaccine production and latest M&A deals Total Revenue EBITDA1 Significant revenue growth of 10.1% to €m €m, adjusted €471.1m, due to +10.1% 32.0%  vaccine production in cooperation with YoY EBITDA BioNTech SE 471.1 Margin 31.6%  revenue contribution of acquisi

  7. Slide 7: Branded pharmaceuticals and other healthcare products

    Branded pharmaceuticals and other healthcare products Continuous growth in existing portfolio Revenue EBITDA1 Revenue growth of 9.8% to €297.7m, due to €m +9.8% €m, adjusted  strong contribution from vitamins and YoY 47.5% 297.7 EBITDA Trommsdorff portfolio 271.2 Margin 45.3%  vaccine production i

  8. Slide 8: Herbal extracts

    Herbal extracts Growth impulses from latest M&A deals Revenue EBITDA1 Revenue growth of 32.1% to €51.9m, due €m €m, adjusted +32.1% to YoY 25.2% 51.9  stable development of Euromed’s extract EBITDA business 39.3 Margin 22.7%  ongoing integration of Cernelle and C3 group +19.2% EBITDA increase of 1

  9. Slide 9: Parallel import business

    Parallel import business Recovery of market and improved profitability Revenue EBITDA Revenue increased by 3.7% to €121.5m, €m €m, adjusted 3.7% due to YoY 121.5  returning growth in PI market 2.0% 117.2  continuous growth in the OTC, narcotics EBITDA and medical cannabis Margin 0.8%  reduced dis

  10. Slide 10: Earnings before tax (Group EBT)

    Earnings before tax (Group EBT) Result decreases due to goodwill impairment of Fitvia group Earnings before tax (EBT)1  EBT decreased by 19.8% to €87.2m €m (unadjusted) resulting in a margin of 25.4% 18.5% EBT Margin Mainly influenced by 18.5% -19.8%  depreciation and amortisation (€51.5m) 108.7 Y

  11. Slide 11: Cash flows and cash conversion

    Cash flows and cash conversion Dedication to future growth Cash flow and cash conversion1  CF from operating activities mainly €m and in % of Group EBITDA influenced by changes in Working 54.1% Capital in 6M 2022 Cash conversion  CF from investing activities reflecting 48.6%  Acquisition of C3 

  12. Slide 12: Balance Sheet of Dermapharm Group

    Balance Sheet of Dermapharm Group Balance sheet as of June 30th 2022  Total assets increased to €1,417m €m (31 December 2021: €1,407m)  Non-current assets increased to €915m 1,417 1,417 (31 December 2021: €888m)  Current assets decreased to €502m Equity (31 December 2021: €519m), mainly due to 

  13. Slide 13: 3 Outlook 2022

    _ is ," tf wa 3 Outlook 2022 T>- Clif. IT

  14. Slide 14: Outlook 2022 Growth strategy

    Outlook 2022 Growth strategy on track – confirming guidance 2022  Growth rates are based on organic growth supported by new launches of in-house developments.  Guidance for the FY 2022 also includes Growth $ growth impulses from M&A deals and the existing cooperation with BioNTech of strategy COVI

  15. Slide 15: Q&A

    4 Q&A 15

  16. Slide 16: Financial calendar

    Financial calendar 2022 Annual Report 2021 CSR Report 2021 Analysts‘ and Half-year Investors‘ Call Annual General Financial Report Capital Markets Day FY 2021 Meeting 2022 as at 30 June 2022 in Brehna 2022 12 April 1 June 7 September 22 November 22 / 29 March 18 May 23 August 16 November 2023 Quarte

  17. Slide 17: Disclaimer

    Disclaimer This publication includes statements, estimates, opinions and projections with respect to the anticipated future performance of Dermapharm Holding SE (together with its consolidated subsidiaries, “Dermapharm”) and such statements, estimates, opinions and projections (“Forward-Looking Stat

  18. Slide 18: For information, please contact

    For information, please contact Britta Hamberger Investor Relations & Corporate Communications Dermapharm Holding SE E-Mail: ir@dermapharm.com Phone: +49 (0) 89 641 86 233 Dermapharm FY 2021 18

Dermapharm Holding — H1 2022 Earnings Presentation on 6ix